Sorrento Therapeutics (NASDAQ: SRNE) is a biopharmaceutical company that focuses on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing unmet medical needs worldwide. The company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. It is developing resiniferatoxin, a non-opiate, ultra-potent, and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. For more information, visit the company’s website at www.sorrentotherapeutics.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
